We are international
Donate
• videos TEXT SIZE   
webcasts from medical meetings    back


The IMF is pleased to present the most comprehensive coverage of the XIth International Myeloma Workshop.

Day 1 Genetics Day 2 Novel treatment approaches
  Microenvironment   Frontline treatment of Myeloma
  Bone Disease   Debate I (Importance of CR)
      Oral presentations I
      Oral presentations II


Day 3 New treatment development Day 4 Oral presentations III
  Stem cell transplant   Debate II - Role of Transplant
  Other plasma cell dyscrasias   Current and Future Perspectives

 

KOS 2007
    next      view all

06.26.07   KOS 2007: Molecular Principles Underlying Myeloma
P. Leif Bergsagel, MD
Mayo Clinic
Scottsdale, AZ, USA

06.26.07   KOS 2007: Molecular Lesions in Multiple Myeloma
Michael Kuehl, MD
National Cancer Institute
Bethesda, MD, USA

06.26.07   KOS 2007: Towards a Molecular-Based Risk Stratification of Multiple Myeloma
J.D. Shaughnessy Jr., MD
Donna D. and Donald M. Lambert Laboratory for Myeloma Genetics
Myeloma Institute for Research and Therapy
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA

06.26.07   KOS 2007: Clinical and Pathological Implications of Myeloma Subtypes
Rafael Fonseca, MD
Mayo Clinic
Scottsdale, AZ, USA

06.26.07   KOS 2007: Prognostic implications of FISH karyotyping in Myeloma
Herve Avet-Loiseau, MD
Laboratory of Hematology
University Hospital
Nantes, France

06.26.07   KOS 2007: Single Nucleotide Polymorphism Models in Myeloma - From the Bank On A Cure SNP Chip
Brian Van Ness, PhD
Bank On A Cure®
International Myeloma Foundation

06.26.07   KOS 2007: Animal Models of Multiple Myeloma: An Overview
Karin Vanderkerken, MD
Vrije Universiteit Brussel (VUB)
Department Hematology and Immunology
Brussels, Belgium

06.26.07   KOS 2007: The Scid-hu model for Multiple Myeloma
Joshua Epstein, MD
Myeloma Institute for Research and Therapy
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA

06.26.07   KOS 2007: Chromosomal and epigenetic abnormalities in MGUS and MM Post-MGUS
Johannes Drach, MD
Medical University of Vienna
Department of Medicine I
Clinical Division of Oncology
Vienna, Austria

06.26.07   KOS 2007: Microarray Analysis to Predict Response to Thalidomide and the IMIDs
Shaji Kumar, MD
Mayo Clinic
Hepatology Department
Rochester, MN, USA